187 tracked 13F filers disclose a position in ZYME as of the latest SEC 13F filings, a combined $1.7B in reported value. Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| # | Fund | Position value | Shares | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | EcoR1 Capital, LLC | $575.2M | 23.0M | —Held | Q1 2026 | |
| 2 | Rubric Capital Management LP | $175.3M | 7.0M | ▲+22% Added · +1.3M sh | Q1 2026 | |
| 3 | BlackRock, Inc. | $114.0M | 4.6M | ▼−0.9% Reduced · −42K sh | Q1 2026 | |
| 4 | BVF INC/IL | $93.5M | 3.7M | ▼−5.2% Reduced · −204K sh | Q1 2026 | |
| 5 | PERCEPTIVE ADVISORS LLC | $87.9M | 3.5M | ▲+7.6% Added · +248K sh | Q1 2026 | |
| 6 | MORGAN STANLEY | $62.1M | 2.5M | ▼−4.3% Reduced · −113K sh | Q1 2026 | |
| 7 | BNP Paribas Asset Management Holding S.A. | $47.8M | 1.9M | ▲+4.7% Added · +86K sh | Q1 2026 | |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | $42.7M | 1.7M | →First observed position No prior filed position | Q1 2026 | |
| 9 | CITADEL ADVISORS LLC | $28.8M | 1.2M | ▲+350% Added · +895K sh | Q1 2026 | |
| 10 | DIMENSIONAL FUND ADVISORS LP | $28.5M | 1.1M | ▼−1.7% Reduced · −20K sh | Q1 2026 | |
| 11 | Nextech Invest Ltd. | $27.9M | 1.1M | —Held | Q1 2026 | |
| 12 | STATE STREET CORP | $28.4M | 1.1M | ▲+7.5% Added · +76K sh | Q2 2026 | |
| 13 | DEUTSCHE BANK AG\ | $23.1M | 921K | ▼−42% Reduced · −675K sh | Q1 2026 | |
| 14 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $18.6M | 744K | ▲+6.3% Added · +44K sh | Q1 2026 | |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | $18.1M | 692K | ▲+4.9% Added · +32K sh | Q2 2026 | |
| 16 | FMR LLC | $16.7M | 667K | ▲+19% Added · +107K sh | Q1 2026 | |
| 17 | Nuveen, LLC | $16.3M | 652K | ▲+0.5% Added · +3K sh | Q1 2026 | |
| 18 | GOLDMAN SACHS GROUP INC | $15.0M | 599K | ▲+43% Added · +179K sh | Q1 2026 | |
| 19 | MPM BioImpact LLC | $14.2M | 565K | ▲New +565K sh | Q1 2026 | |
| 20 | Prosight Management, LP | $13.5M | 539K | ▲+1.6% Added · +9K sh | Q1 2026 | |
| 21 | Qube Research & Technologies Ltd | $12.8M | 512K | ▲+7.9% Added · +38K sh | Q1 2026 | |
| 22 | VANGUARD PORTFOLIO MANAGEMENT LLC | $12.5M | 500K | →First observed position No prior filed position | Q1 2026 | |
| 23 | Redmile Group, LLC | $12.3M | 492K | —Held | Q1 2026 | |
| 24 | Capricorn Fund Managers Ltd | $12.7M | 487K | ▼−52% Reduced · −521K sh | Q2 2026 | |
| 25 | Hillsdale Investment Management Inc. | $8.7M | 346K | ▲+45% Added · +108K sh | Q1 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
Last quarter, 7 funds opened a new position in ZYME and 30 added to an existing one, while 11 reduced and 0 exited entirely — based on 13F filings from active, signal-eligible managers (passive index funds and other mechanical holders are excluded from this count).
| Company | Co-held by | Combined value |
|---|---|---|
| AMAZON.COM INCAMZN | 93 funds | $164.6B |
| MICROSOFT CORPMSFT | 92 funds | $230.0B |
| META PLATFORMS INC-CLASS AMETA | 92 funds | $90.9B |
| NVIDIA CORPNVDA | 91 funds | $329.8B |
| BROADCOM INCAVGO | 91 funds | $133.0B |
| ELI LILLY & COLLY | 91 funds | $65.4B |
| APPLE INCAAPL | 90 funds | $249.8B |
| LAM RESEARCH CORPLRCX | 90 funds | $29.0B |
| MICRON TECHNOLOGY INCMU | 90 funds | $28.3B |
| COSTCO WHOLESALE CORPCOST | 88 funds | $31.8B |
| ALPHABET INC-CL AGOOGL | 87 funds | $142.5B |
| MASTERCARD INC - AMA | 87 funds | $44.8B |
Ranked by how many of ZYME's institutional holders also hold each name, a cross-fund conviction signal.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Jan 12, 2026 | Galbraith Kenneth | Chair & CEO, Director | Sell (S) | 30K | $690K |
| Jan 12, 2026 | Moore Paul Andrew | Chief Scientific Officer | Sell (S) | 10K | $217K |
| Jan 12, 2026 | Smith Jeffrey T L | EVP & Chief Medical Officer | Sell (S) | 9K | $211K |
| Jan 12, 2026 | Hollywood Mark | EVP & Chief Operating Officer | Sell (S) | 6K | $139K |
| Jan 5, 2026 | Moore Paul Andrew | Chief Scientific Officer | Sell (S) | 11K | $272K |
| Jan 5, 2026 | Moore Paul Andrew | Chief Scientific Officer | Sell (S) | 9K | $233K |
| Jan 5, 2026 | Galbraith Kenneth | Chair & CEO, Director | Sell (S) | 32K | $795K |
| Jan 5, 2026 | Galbraith Kenneth | Chair & CEO, Director | Sell (S) | 23K | $569K |
| Jan 5, 2026 | Smith Jeffrey T L | EVP & Chief Medical Officer | Sell (S) | 11K | $265K |
| Dec 22, 2025 | Galbraith Kenneth | Chair & CEO, Director | Sell (S) | 48K | $1.3M |
| May 19, 2025 | EcoR1 Capital, LLC | Director, 10% Owner | Buy (P) | 6K | $70K |
| May 15, 2025 | EcoR1 Capital, LLC | Director, 10% Owner | Buy (P) | 50K | $566K |
Connected entities for ZYME
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/ZYME/capital-change-brief"
Use Arkolith's capital_change_brief for ZYME. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for ZYME. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes.